News
BSTG
4.700
+9.30%
0.400
Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience repairing the esophagus following cancer surgery and FDA approval to commence a clinical trial of the Biostage Esopha...
PR Newswire · 06/15 12:30
Insider Buy: Biostage
MT Newswires · 05/23 16:03
Biostage reports Q1 results
Biostage press release (OTC:BSTG): Q1 GAAP EPS of -$0.20. As of March 31, 2022, the company had operating cash on-hand of $0.7 million. Expects that its current cash will be sufficient to fund
Seekingalpha · 05/16 20:17
Cell-therapy biotechnology company Biostage raises ~$5.1M to advance clinical trial
Cell-therapy biotechnology company, Biostage (OTC:BSTG) raises ~$5.1M from new and existing investors in a private placement of its shares.  The funds will be used to accelerate the clinical development of Biostage's
Seekingalpha · 05/13 14:00
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 05/10 12:30
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a...
PR Newswire · 04/11 12:30
Biostage GAAP EPS of -$0.55
Biostage press release (OTC:BSTG): Q4 GAAP EPS of -$0.55. The company expects that operating cash on-hand as of December 31, 2021 of $1.2M will enable us to fund operating expenses
Seekingalpha · 04/01 11:43
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 03/30 18:49
Biostage rebounds after announcing court ruling against insurance carrier
Biostage (OTC:BSTG +6.1%) shares have made a comeback after announcing that a Court ordered its medical liability insurance carrier, Medmarc, breached its duty to defend the company in a lawsuit
Seekingalpha · 01/25 17:44
Biostage Says Court Orders Medical Liability Insurance Carrier to Pay Its Litigation Costs; Shares Rise
MT Newswires · 01/25 15:23
BRIEF-Biostage Announces "Meet The Founder, New Chairman And Interim CEO" Webinar
reuters.com · 01/25 14:37
BRIEF-Biostage Announces Court's Preliminary Injunction Order Requiring Its Insurance Carrier To Continue Paying For Defense
reuters.com · 01/25 14:19
Biostage announces "meet the founder, new chairman and interim CEO" webinar
Biostage (OTC:BSTG) will be hosting a webinar to allow investors to meet its new Interim CEO, David Green. Mr. Green is also Biostage's founder and is the Chairman of its
Seekingalpha · 01/25 14:02
Biostage Announces "Meet the Founder, New Chairman and Interim CEO" Webinar
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 01/25 13:30
Biostage Announces Court's Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 01/25 13:00
New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, to...
PR Newswire · 01/10 22:01
5 Penny Stocks Insiders Are Buying
  When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 12/01/2021 13:46
Biostage hires David Green as executive chief
Biostage (OTC:BSTG) hires David Green as its CEO and appointed Mr. Green as Chairman of the Board of Directors. Mr. Green is the founder and CEO of Zero CarbonTM LLC, an energy-efficiency business. He is also
Seekingalpha · 11/30/2021 14:02
BRIEF-Biostage Hires David Green As Chief Executive Officer
reuters.com · 11/30/2021 13:32
More
Webull provides a variety of real-time BSTG stock news. You can receive the latest news about Biostage through multiple platforms. This information may help you make smarter investment decisions.
About BSTG
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.